Sugi Predict

Sugi Predict / Compounds / SCHEMBL5683128

SCHEMBL5683128

SCHEMBL5683128

Nc1nc2cc(OC(F)(F)F)ccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ GMNN O75496 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ SCN4A P35499 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ PDE4D Q08499 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9765811 0.98 NPC1 (0.49) NPC1RAB9AGAAGMNNUSP2
SCHEMBL5680087 0.88 TYMS (0.44) NPC1RAB9AGAAGMNNUSP2
SCHEMBL5807225 0.87 SCN10A (0.56) NPC1RAB9AGAAGMNNUSP2
Hydrochloric Acid SCHEMBL9765815 0.86 SCN10A (0.55) NPC1RAB9AGAAGMNNUSP2
SCHEMBL5680030 0.84 XDH (0.58) CYP1A2CYP3A4CYP2C9XDHKMT2A
SCHEMBL10833668 0.84 FABP6 (0.46) CYP1A2XDHKMT2ATYMSMASP2
Bromide SCHEMBL2380560 0.83 XDH (0.57) CYP1A2CYP3A4CYP2C9XDHKMT2A
SCHEMBL1193332 0.81 RUNX1 (0.43) NPC1RAB9AGAAGMNNUSP2
SCHEMBL18190876 0.81 RUNX1 (0.43) NPC1RAB9AGAAGMNNUSP2
SCHEMBL7066940 0.81 RUNX1 (0.43) NPC1RAB9AGAAGMNNUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5049574-A Psychotic diseases RHONE-POULENC SANTE (FR) 1991-09-17 — — US claimed
JP-2264762-A — — None — — JP disclosed
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 — — US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 — — US disclosed
US-12472165-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-11-18 — — US disclosed
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD (US) 2025-10-30 — — US disclosed
US-12295942-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-05-13 — — US disclosed
US-12213965-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-02-04 — — US disclosed
US-12005046-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 — — US disclosed
US-12005047-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 — — US disclosed
WO-2016140879-A9 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2016-11-03 — — WO disclosed
WO-2016140878-A9 PRODRUGS RILUZOLE AND THEIR METHOD OF USE BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2016-10-20 — — WO disclosed
WO-2008075109-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
EP-1620413-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2006-02-01 — — EP disclosed
WO-2004098494-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-11-18 — — WO disclosed
US-5049574-A Psychotic diseases RHONE-POULENC SANTE (FR) 1991-09-17 — — US disclosed
US-5049574-A Psychotic diseases RHONE-POULENC SANTE (FR) 1991-09-17 — — US disclosed
US-5049574-A Psychotic diseases RHONE-POULENC SANTE (FR) 1991-09-17 — — US disclosed
JP-H02264762-A 5-TRIFLUOROMETHOXY-2-MBENZIMIDAZOLAMINE, PREPARATION THEREOF AND USE THEREOF RHONE POULENC SANTE 1990-10-29 — — JP disclosed
EP-0384812-A1 5-Trifluoromethoxy-2-aminobenzimidazole, process for its preparation and medicaments containing same RHONE-POULENC SANTE (FR) 1990-08-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 NPC1 1564/4885RAB9A 893/4885GAA 2244/4885
US-12005046-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885
US-12005047-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 NPC1 1610/4885RAB9A 914/4885GAA 2222/4885
US-12472165-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885
US-12295942-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885
US-12213965-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 NPC1 3564/4885RAB9A 985/4885GAA 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.